Summary of TEAEs during the overall study period (safety population)
| . | CT-P10 (n = 70) . | Rituximab (n = 70) . |
|---|---|---|
| Patients with ≥1 TEAE | ||
| Any TEAE | 63 (90) | 60 (86) |
| Study drug related | 40 (57) | 38 (54) |
| Grade ≥4 TEAE | 12 (17) | 7 (10) |
| Study drug related | 5 (7) | 5 (7) |
| TESAE | 24 (34) | 13 (19) |
| Study drug related | 7 (10) | 6 (9) |
| Patients with ≥1 TEAE due to IRR | 16 (23) | 19 (27) |
| Patients with ≥1 TEAE due to infection | 35 (50) | 32 (46) |
| Patients with ≥1 TEAE leading to treatment discontinuation | 10 (14) | 5 (7) |
| Study drug related | 3 (4) | 3 (4) |
| . | CT-P10 (n = 70) . | Rituximab (n = 70) . |
|---|---|---|
| Patients with ≥1 TEAE | ||
| Any TEAE | 63 (90) | 60 (86) |
| Study drug related | 40 (57) | 38 (54) |
| Grade ≥4 TEAE | 12 (17) | 7 (10) |
| Study drug related | 5 (7) | 5 (7) |
| TESAE | 24 (34) | 13 (19) |
| Study drug related | 7 (10) | 6 (9) |
| Patients with ≥1 TEAE due to IRR | 16 (23) | 19 (27) |
| Patients with ≥1 TEAE due to infection | 35 (50) | 32 (46) |
| Patients with ≥1 TEAE leading to treatment discontinuation | 10 (14) | 5 (7) |
| Study drug related | 3 (4) | 3 (4) |
Data are n (%) of patients.